# Niraparib/TTFields in GBM

> **NCT04221503** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma
- Recurrent Glioblastoma
- GBM

## Interventions

- **DRUG:** Niraparib
- **DEVICE:** Optune
- **PROCEDURE:** Planned surgical resection

## Key facts

- **NCT ID:** NCT04221503
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-30
- **Primary completion:** 2026-01
- **Final completion:** 2026-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221503, "Niraparib/TTFields in GBM". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04221503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*